Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies

Journal of Clinical Oncology

Volumn 20, Issue 6, 2002, Pages 1692-1703

  Heinrich, Michael C ^a   Blanke, Charles D ^a   Druker, Brian J ^a   Corless, Christopher L ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANTINEOPLASTIC AGENT; CARBOPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; IRINOTECAN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; SU 4984; SU 5614; SU 6577; UNCLASSIFIED DRUG; VATALANIB;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BLEEDING; BREAST CARCINOMA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG TARGETING; ELECTROLYTE DISTURBANCE; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TUMOR; GENE MUTATION; HUMAN; LEUKEMIA; MASTOCYTOSIS; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SEMINOMA;

ANGIOGENESIS INHIBITORS; ENZYME INHIBITORS; HUMANS; INDOLES; MUTATION; NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES;

EID: 0037087531     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.6.1692     Document Type: Review

References (133)

1. Human protooncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand
2. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family
3. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells
4. Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulin-like domains
5. Ultrastructural identification of the c-kit-expressing interstitial cells in the rat stomach: A comparison of control and Ws/Ws mutant rats
6. Hereditary anemias of the mouse: A review for geneticists
7. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice: Evidence for an impaired c-kit kinase in mutant mice
8. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues
9. Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors
10. The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locus
11. Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis
12. A specific combination of substrates is involved in signal transduction by the kit-encoded receptor
13. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis
14. Utility of paraffin section immunohistochemistry for C-KIT (CD117) in the differential diagnosis of systemic mast cell disease involving the bone marrow
15. Paraffin section detection of the c-kit gene product (CD117) in human tissues: Value in the diagnosis of mast cell disorders
16. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
17. Gastrointestinal stromal tumors: Definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis
18. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan
19. Activating c-kit gene mutations in human germ cell tumors
20. Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours
21. Differential expression of the c-kit proto-oncogene in germ cell tumours
22. Expression of the c-kit protein product in carcinoma-in-situ and invasive testicular germ cell tumours
23. Spermatocytic seminoma as compared to classical seminoma: An immunohistochemical and DNA flow cytometric study
24. c-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi
25. Proto-oncogene c-kit expression in malignant melanoma: Protein loss with tumor progression
26. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma
27. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma
28. Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis
29. Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor
30. Increased expression of c-Kit or its ligand Steel Factor is not a common feature of adult acute myeloid leukaemia
31. Serum soluble c-kit receptor and expression of c-kit protein and mRNA in acute myeloid leukemia
32. Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas
33. KIT expression in angiosarcomas and fetal endothelial cells: Lack of mutations of exon 11 and exon 17 of C-kit
34. Expression of c-kit (CD117) in benign and malignant human endometrial epithelium
35. Expression and regulation of c-kit receptor and response to stem cell factor in childhood malignant T-lymphoblastic cells
36. Coexpression of the c-kit and stem cell factor genes in breast carcinomas
37. Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues
38. Expression of c-kit and kit-ligand in benign and malignant prostatic tissues
39. Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells
40. Implication of tyrosine kinase receptor and steel factor in cell density-dependent growth in cervical cancers and leukemias
41. An in vivo model for receptor tyrosine kinase autocrine/paracrine activation: Auto-stimulated KIT receptor acts as a tumor promoting factor in papillomavirus-induced tumorigenesis
42. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer
43. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene
44. Expression of stem cell factor and c-kit in human neuroblastoma
45. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
46. Stem cell factor suppresses apoptosis in neuroblastoma cell lines
47. Activating mutations of c-kit at Asp816 are associated with constitutive activation of Stat signal transduction pathways in acute myeloid leukemia
48. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation
49. RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia
50. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP- 1 promoter
51. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo
52. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhbitor
53. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site
54. Effects of rrSCF on multiple cytokine responsive HPP CFC generated from SCA+Linmurine hematopoietic progenitors
55. Requirement for mast cell growth factor for primordial germ cell survival in culture
56. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor
57. Internal tandem duplications of the Flt3 juxtamembrane domain results in factor-independent growth of 32D cells
58. Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region
59. A single amino acid substitution in a WW-like domain of diverse members of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation
60. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines
61. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors
62. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors: A study of 200 cases
63. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours
64. A transforming mutation enhances the activity of the c-Kit soluhle tyrosine kinase domain
65. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1
66. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
67. Role of aspartic acid 814 in the function and expression of c-kit receptor tyrosine kinase
68. C-kit mutations in core binding factor leukemias
69. Human piebald trait resulting from a dominant negative mutant allele of the c-kit membrane receptor gene
70. Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism
71. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
72. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
73. Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells
74. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
75. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells
76. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
77. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
78. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors
79. Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
80. Phase I trial of a specific ABL tyrosine kinase inhibitor, CGP 57148, in interferon refractory chronic myelogenous leukemia patients
81. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia
82. Chronic myeloid leukemia: Current treatment options
83. Chronic myelogenous leukemia
84. SU5416 in advanced colorectal cancer (CRC): A University of Chicago Phase II Consortium Study
85. Efficacy results of a phase I/II study of SU5416 (S)/5-fluorouracil (F)/leucovorin (L) relative to results in random subsets of similar patients (Pts) from a phase III study of irinotecan (C)/F/L or F/L alone in the therapy of previously untreated metastatic colorectal cancer (MCRC)
86. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer
87. Phase I/II study of SU5416 in combination with irinotecan/5-FU/LV (IFL) in patients with metastatic colorectal cancer
88. A phase I pharmacokinetic and pharmacodynamic study of SU5416 and doxorubicin (ADR) in inflammatory breast cancer (IBC)
89. A phase I/II trial and pharmacokinetic (PK) study of SU5416 in combination with paclitaxel/carboplatin
90. A phase II study with SU5416 in patients with C-Kit positive AML
91. A phase I and pharmacokinetic study of single oral administration of SU5416 in patients with advanced solid tumors
92. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
93. Phase I experience with SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies
94. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia
95. Trisomy 4 leading to duplication of a mutated KIT allele in acute myeloid leukemia with mast cell involvement
96. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications
97. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors
98. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene
99. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behavior
100. A new c-kit mutation in a case of aggressive mast cell disease
101. Effects of the tyrosine kinase inhibitor STI571 on mutated kit and neoplastic cells
102. ST1571 inhibits the kinase activity of wild type and juxtamembrane c-kit mutants but not the exon 17 D816V mutation associated with mastocytosis
103. Effects of the tyrosine kinase inhibitor STI571 on the kinase activity of wild type and various mutated c-kit receptors found in mast cell neoplasms
104. Mesenchymal tumors of the gastrointestinal tract: A paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal diseases?
105. Gastrointestinal stromal tumors: Value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas
106. Immunohistologic characterization of gastrointestinal stromal tumors: A study of 82 cases compared with 11 cases of leiomyomas
107. A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors
108. CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34
109. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours
110. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: Dependence on anatomic site
111. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases
112. Differentiation and risk assessment of gastrointestinal stromal tumors
113. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas
114. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors
115. Familial gastrointestinal stromal tumor with hyperpigmentation: Association with a germline mutation of the c-kit gene
116. Recurrent gastrointestinal stromal sarcomas
117. Gastrointestinal stromal tumors
118. Contrast of response to D-MAP + Sargramostim between patients with advance malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas
119. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
120. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing c-kit (CD117)
121. STI571, an active drug in metastatic gastrointestinal stromal tumors (GIST) an EORTC phase I study
122. A proposed classification of mastocytosis incorporating molecular genetics
123. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells
124. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
125. Gonadal expression of c-kit encoded at the W locus of the mouse
126. Effect of the W mutation, for white belly spot, on testicular germ cell differentiation in mice
127. The role of stem cell factor and of alternative c-kit gene products in the establishment, maintenance and function of germ cells
128. Migration and ultrastructural localization of the c-kit receptor protein in spermatogenic cells and spermatozoa of the mouse
129. Kit ligand mediates survival of type A spermatogonia and dividing spermatocytes in postnatal mouse testes
130. Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3′-kinase is essential for male fertility
131. Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer
132. c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells
133. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth